Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 4/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.52 |
| ▸ | PTGES | O14684 | 8/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PPIA | P62937 | 1/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10212118 | 0.87 | DPP4 (0.52) | TP53DPP4DPP7PTGESKCNH2 | |
| SCHEMBL30681561 | 0.83 | LMNA (0.62) | TP53LMNAGAADPP4DPP7 | |
| SCHEMBL1819622 | 0.83 | LMNA (0.62) | TP53LMNAGAADPP4DPP7 | |
| SCHEMBL30200324 | 0.81 | GAA (0.56) | GAA | |
| SCHEMBL6930440 | 0.79 | LMNA (0.63) | LMNAGAAPTGES | |
| SCHEMBL13161963 | 0.79 | NPC1 (0.65) | GAA | |
| SCHEMBL4755705 | 0.77 | DPP4 (0.60) | TP53LMNAGAADPP4DPP7 | |
| SCHEMBL18397964 | 0.74 | GAA (0.60) | TP53LMNAGAARECQL | |
| SCHEMBL1222596 | 0.74 | POLB (0.56) | LMNADPP4DPP7KCNH2 | |
| SCHEMBL4345747 | 0.73 | CARM1 (0.56) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132492-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | JINAN UNIVERSITY (CN) | 2024-04-25 | — | — | US | disclosed |
| CN-115348963-B | Pyridopyrimidine compound and application thereof | 暨南大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| CN-115348963-A | Pyridopyrimidine compound and application thereof | 暨南大学 | 2022-11-15 | — | — | CN | disclosed |
| WO-2022188755-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | 暨南大学 | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132492-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | AKT3, AKT1S1, AKT2 | TP53 118/4885LMNA 4085/4885GAA 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.